贝斯美 reported revenue of ¥0.75B for the period ended 2026-06-30, -3.6% year on year. Net income was ¥0.00B, a 0.2% net margin on a 19.6% gross margin. The largest revenue line is 二甲戊灵原药 at 33% of the total. Free cash flow for the period was ¥-0.07B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.75B | -3.6% |
| Gross profit | ¥0.15B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.00B | -96.3% |
| Gross margin | 19.6% | Net margin 0.2% |
| Revenue Q/Q | +11.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 二甲戊灵原药 | ¥0.25B | 32.8% |
| 贸易类除草剂 | ¥0.20B | 26.9% |
| 贸易类杀虫剂 | ¥0.12B | 15.8% |
| 贸易类杀菌剂 | ¥0.08B | 10.9% |
| 碳五系列产品 | ¥0.05B | 6.2% |
| 农药中间体 | ¥0.04B | 4.7% |
| 二甲戊灵制剂 | ¥0.01B | 1.9% |
| 贸易类其他化工产品 | ¥0.00B | 0.6% |
| 其它 | ¥0.00B | 0.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.60B | 80.4% |
| R&D | ¥0.02B | 2.5% |
| SG&A | ¥0.09B | 11.9% |
| Tax & other | ¥0.01B | 0.7% |
| Item | Amount |
|---|---|
| Total assets | ¥3.34B |
| Total liabilities | ¥1.58B |
| Shareholders' equity | ¥1.76B |
| Equity / assets | 52.8% |
| Operating cash flow | ¥-0.03B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥-0.07B |
| Cash conversion (OCF / net income) | -7686% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
钢研纳克 ・ 锦鸡股份 ・ 力合科技 ・ 泰和科技 ・ 矩子科技 ・ 广康生化 ・ 电声股份 ・ 斯迪克 ・ 天迈科技 ・ 久量股份 ・ 华辰装备 ・ 中科海讯
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies